For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $15.05 in the prior trading day, Alignment Healthcare Inc (NASDAQ: ALHC) closed at $15.29, up 1.59%. In other words, the price has increased by $1.59 from its previous closing price. On the day, 3.06 million shares were traded. ALHC stock price reached its highest trading level at $15.81 during the session, while it also had its lowest trading level at $14.92.
Ratios:
Our goal is to gain a better understanding of ALHC by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 2.34.
On December 03, 2024, Stephens Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $13 to $17.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Kim Hyong sold 18,600 shares for $15.03 per share. The transaction valued at 279,608 led to the insider holds 472,167 shares of the business.
Maroney Dawn Christine sold 30,000 shares of ALHC for $447,108 on Aug 13 ’25. The President now owns 2,012,899 shares after completing the transaction at $14.90 per share. On Aug 11 ’25, another insider, Kim Hyong, who serves as the Chief Medical Officer of the company, sold 18,600 shares for $14.54 each. As a result, the insider received 270,425 and left with 490,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 3027894016 and an Enterprise Value of 2853779456. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.91 while its Price-to-Book (P/B) ratio in mrq is 21.47. Its current Enterprise Value per Revenue stands at 0.855 whereas that against EBITDA is 362.799.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.17, which has changed by 0.8009423 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $21.06, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 11.16%, while the 200-Day Moving Average is calculated to be 6.29%.
Shares Statistics:
The stock has traded on average 3.41M shares per day over the past 3-months and 2909330 shares per day over the last 10 days, according to various share statistics. A total of 197.96M shares are outstanding, with a floating share count of 136.03M. Insiders hold about 33.62% of the company’s shares, while institutions hold 74.12% stake in the company. Shares short for ALHC as of 1753920000 were 13476373 with a Short Ratio of 3.95, compared to 1751241600 on 12618961. Therefore, it implies a Short% of Shares Outstanding of 13476373 and a Short% of Float of 10.479999.
Earnings Estimates
The current market rating for Alignment Healthcare Inc (ALHC) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.18 and $0.11 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.32, with 4.0 analysts recommending between $0.4 and $0.26.
Revenue Estimates
10 analysts predict $980.9M in revenue for the current quarter. It ranges from a high estimate of $983.6M to a low estimate of $978M. As of the current estimate, Alignment Healthcare Inc’s year-ago sales were $692.43MFor the next quarter, 10 analysts are estimating revenue of $977.65M. There is a high estimate of $984.01M for the next quarter, whereas the lowest estimate is $968M.
A total of 10 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $3.91B, while the lowest revenue estimate was $3.89B, resulting in an average revenue estimate of $3.9B. In the same quarter a year ago, actual revenue was $2.7BBased on 10 analysts’ estimates, the company’s revenue will be $4.97B in the next fiscal year. The high estimate is $5.47B and the low estimate is $4.77B.
